Correlation Between Pfizer and Molecular Partners

Can any of the company-specific risk be diversified away by investing in both Pfizer and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pfizer and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Pfizer Inc and Molecular Partners AG, you can compare the effects of market volatilities on Pfizer and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pfizer with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pfizer and Molecular Partners.

Diversification Opportunities for Pfizer and Molecular Partners

-0.36

Correlation Coefficient

Pfizer  Molecular Partners

Very good diversification

The 3 months correlation between Pfizer and Molecular is -0.36. Overlapping area represents the amount of risk that can be diversified away by holding Pfizer Inc and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Pfizer is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pfizer Inc are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Pfizer i.e., Pfizer and Molecular Partners go up and down completely randomly.

Pair Corralation between Pfizer and Molecular Partners

Considering the 90-day investment horizon Pfizer Inc is expected to under-perform the Molecular Partners. But the stock apears to be less risky and, when comparing its historical volatility, Pfizer Inc is 3.72 times less risky than Molecular Partners. The stock trades about -0.07 of its potential returns per unit of risk. The Molecular Partners AG is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest  655.00  in Molecular Partners AG on September 20, 2024 and sell it today you would lose (125.00) from holding Molecular Partners AG or give up 19.08% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	99.8%
Values	Daily Returns

Pfizer Inc  vs.  Molecular Partners AG

Pfizer Inc

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Pfizer Inc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's technical and fundamental indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.

Molecular Partners

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Molecular Partners AG are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain essential indicators, Molecular Partners displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Pfizer and Molecular Partners

The main advantage of trading using opposite Pfizer and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pfizer position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.

The idea behind Pfizer Inc and Molecular Partners AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.